Abstract
<b>Background:</b> Although short-term efficacy of lumacaftor/ivacaftor and tezacaftor/ivacaftor is clearly established in randomized trials, data on long-term effectiveness is limited. <b>Aim:</b> This registry-based cohort study assessed longitudinal outcomes of F508del-homozygous people with CF aged 12 years and older, up to 3 years after the introduction of the dual Cystic Fibrosis transmembrane conductancance regulator (CFTR) modulators. <b>Methods:</b> Annual data (2010-2019) were retrieved from the Dutch Cystic Fibrosis Registry. Longitudinal trends in percent predicted forced expiratory volume in 1s (ppFEV1) decline, body mass index (BMI), BMI Z-score and intravenous antibiotic treatment duration before and after CFTR modulator initiation were assessed with linear and negative binomial mixed models. <b>Results:</b> We included 401 participants. ppFEV1 decline improved from -0.88%/year to -0.33%/year after modulator initiation (change:0.55%/year, CI:0.04–1.07, p=0.037). In adults, annual BMI trend was not altered (change:0.10 kg/m²/year, CI:-0.01–0.20, p=0.085). Annual BMI Z-score in children reversed from -0.05/year before modulator treatment to 0.09/year afterwards (change:0.14/year, CI:0.06–0.22, p<0.001). Intravenous antibiotic treatment duration showed a three-fold reduction in the first year after modulator initiation (IRR:0.28, CI:0.19–0.40, p<0.001), but the annual trend did not change in subsequent years (IRR:1.15, CI:0.92–1.46, p=0.231). <b>Conclusion:</b> Long-term ppFEV1 decline improved after the introduction of LUM/IVA and TEZ/IVA, which was also observed for BMI Z-score in children, but not BMI in adults. Intravenous antibiotic use was reduced in the first year after modulator initiation, but increased in subsequent years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have